BIRC5 and neoplasm: SurVaxM (SVN53-67/M57-KLH, DRU-2017-5947) is a 14 amino acid peptide from the human survivin protein sequence and serves as a neo-immunogen that initiates an immune response to survivin containing tumor cells, and thus can sensitize cancer cells to immune mediated apoptosis by targeting survivin that is differentially over-expressed in tumor cells compared to normal cells [263,264,265].